

Sartorius Stedim Biotech

Agenda of the Annual Combined Shareholders 'Meeting

of March 25, 2025

SARTORIUS STEDIM BIOTECH
A public limited company ("*société anonyme*") with a share capital of €19,466,081
Registered office: Zone Industrielle Les Paluds Avenue de Jouques 13400 AUBAGNE
314 093 352 R.C.S. MARSEILLE

**AGENDA OF THE SHAREHOLDERS' MEETING
OF MARCH 25, 2025**

Agenda

Extraordinary Part

- Reading of the Board of Directors' report on the proposed resolutions of the Shareholders' Meeting;
- 1. Amendments to article 15.3 of the Company's articles of association;
- 2. Amendments to article 17.5 of the Company's articles of association;

Ordinary Part

- Reading of the Board of Directors' management report on the financial statements, including the Group management report;
- Reading of the Board of Directors' report on the proposed resolutions of the Shareholders' Meeting;
- Reading of the Board of Directors' corporate governance report;
- Reading of the Statutory Auditors' report on the Company's financial statements for the financial year ended on 31 December 2024;
- Reading of the Statutory Auditors' report on the consolidated financial statements for the financial year ended on 31 December 2024;
- Reading of the Statutory Auditor's report on the regulated agreements covered by Article L. 225-38 et seq. of the French Commercial Code;
- 3. Approval of the financial statements for the financial year ended on 31 December 2024 and discharge to all Directors;
- 4. Approval of the consolidated financial statements for the financial year ended on 31 December 2024;
- 5. Allocation of the financial result for the financial year ended on 31 December 2024;
- 6. Approval of the remuneration policy and determination of the amount of the total annual remuneration to be allocated to the Board of Directors for the 2025 financial year;

7. Approval of the information mentioned in Article L. 22-10-9 of the French Commercial Code concerning the remuneration paid or awarded to the corporate officers for the 2024 financial year;
8. Approval of the fixed, variable and extraordinary components of the remuneration and the benefits of all kinds paid or awarded to the Chairman of the Board of Directors for the 2024 financial year;
9. Approval of the fixed, variable and extraordinary components of the remuneration and the benefits of all kinds paid or awarded to the Chief Executive Officer for the 2024 financial year;
10. Approval of the remuneration policy of the Chairman of the Board of Directors for the 2025 financial year;
11. Approval of the remuneration policy of the Chief Executive Officer for the 2025 financial year;
12. Renewal of the term of office of Mr. Joachim Kreuzburg as Director;
13. Renewal of the term of office of Mr. René Fáber as Director;
14. Renewal of the term of office of Mrs. Pascale Boissel as Director;
15. Renewal of the term of office of Mr. Lothar Kappich as Director;
16. Appointment of Mr. Christopher Nowers as Director;
17. Appointment of Mrs. Cécile Dussart as Director;
18. Authorization granted to the Board of Directors to enable the Company to trade in its own shares;

Extraordinary Part

- Reading of the Board of Directors' report on the proposed resolutions of the Shareholders' Meeting;
 - Reading of the Statutory Auditors' special report;
19. Delegation of authority granted to the Board of Directors to issue shares and/or securities giving access to the share capital of the Company and/or securities giving the right to the allotment of debt instruments, with preferential subscription rights of the shareholders;
 20. Delegation of authority granted to the Board of Directors to issue shares and/or securities giving or capable of giving access to the share capital of the Company and/or securities giving the right to the allotment of debt instruments, without preferential subscription rights of the shareholders, through public offerings other than those referred to in Article L. 411-2 of the French Monetary and Financial Code;
 21. Delegation of authority granted to the Board of Directors to issue shares and/or securities giving or capable of giving access to the share capital of the Company and/or the issuance of securities giving the right to the allotment of debt instruments, without preferential subscription rights of the

shareholders, through public offerings addressed exclusively to qualified investors or to a restricted circle of investors as defined in Article L. 411-2 of the French Monetary and Financial Code;

22. Delegation of authority granted to the Board of Directors to issue shares without preferential subscription rights of the shareholders, to named beneficiaries;
23. Delegation of authority to the Board of Directors to increase the number of shares and/or securities giving or capable of giving access to the share capital of the Company to be issued in case of share capital increase, with or without preferential subscription rights of the shareholders;
24. Delegation of authority granted to the Board of Directors to decide to issue shares and/or securities giving or capable of giving access to the share capital of the Company as consideration for contributions in kind in shares and/or securities giving or capable of giving access to capital, without preferential subscription rights of shareholders;
25. Delegation of authority granted to the Board of Directors to increase the share capital of the Company through the capitalization of reserves, earnings or premiums or any other sum upon which capitalization would be permitted;
26. Delegation of authority granted to the Board of Directors to issue shares and/or securities giving or capable of giving access to the share capital of the Company, reserved for members of company savings plan, without preferential subscription rights of the shareholders;
27. Delegation of authority granted to the Board of Directors to grant free new or existing shares to the benefit of employees or corporate officers, in the limit of 10% of the capital;
28. Delegation of authority granted to the Board of Directors to reduce the capital in accordance with Article L. 22-10-62 of the French Commercial Code.